*Department of Anesthesiology and Perioperative Medicine, University of Rochester School of Medicine and Dentistry, Rochester
∥Department of Psychology, Syracuse University, Syracuse, NY
†Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women’s Hospital
‡Department of Psychiatry
††Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
§Department of Anesthesiology and Perioperative Medicine, University of Pittsburgh, Pittsburgh, PA
¶World Patients Alliance, Washington, DC
#Department of Family and Community Medicine, University of Toronto
**Addictions Division, Centre for Addiction and Mental Health, Toronto, CA
J.S.G.: design of the survey, performed the analyses, wrote the first draft of the manuscript, and incorporated coauthor feedback. R.R.E., K.P.H., A.D.W., P.C., and R.F.: design of the survey, interpretation of the results, and provided feedback on the first draft of the manuscript. J.E.H., E.C.L., and S.B.: data cleaning and categorizing free text responses and provided feedback on the manuscript. B.L.F.: interpretation of the results and provided feedback on the first draft of the manuscript, J.W.D.: decisions regarding categorizing free text responses, interpretation of the results, and provided feedback on the first draft of the manuscript.
GW Pharmaceuticals (Cambridgeshire, UK) provided funds to support the conduct of the survey, including consulting fees too. The analyses and writing of this manuscript were supported by NIH (Bethesda, MD) grant K24NS126861. R.F., J.S.G., K.P.H., R.R.E., and A.D.W. received consulting fees from GW to design the survey. B.L.F. has obtained funding from Pfizer Inc. (GRAND Awards, including salary support) for investigator-initiated projects; Indivior for a clinical trial sponsored by Indivior. B.L.F. has in-kind donations of cannabis products from Aurora Cannabis Enterprises Inc. and study medication donations from Pfizer Inc. (varenicline for smoking cessation) and Bioprojet Pharma. He was also provided a coil for a Transcranial magnetic stimulation (TMS) study from Brainsway. B.L.F. has obtained industry funding from Canopy Growth Corporation (through research grants handled by the Centre for Addiction and Mental Health and the University of Toronto), Bioprojet Pharma, Alcohol Countermeasure Systems (ACS), Alkermes and Universal Ibogaine. He has participated in a session of a National Advisory Board Meeting (Emerging Trends BUP-XR) for Indivior Canada and has been consultant for Shinogi. He is supported by CAMH, Waypoint Centre for Mental Health Care, a clinician-scientist award from the department of Family and Community Medicine of the University of Toronto, and a Chair in Addiction Psychiatry from the department of Psychiatry of University of Toronto. The remaining authors declare no conflict of interest.
Reprints: Jennifer S. Gewandter, PhD, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, P.O. Box 604, Rochester, NY 14642 (email: [email protected]).
Supplemental Digital Content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal's website, www.clinicalpain.com.
